论文信息 - 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Preamble and Transition to ACC/AHA Guidelines to Reduce Cardiovascular Risk S2 The goals of the …

[1] J. Stamler. Clofibrate and niacin in coronary heart disease. , 1975, JAMA.

[2] C. E. Becker. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. , 1984, JAMA.

[3] The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. , 1984, JAMA.

[4] J. Stamler,et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. , 1986, Journal of the American College of Cardiology.

[5] J. Huttunen,et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[6] J. Crouse,et al. Hypertriglyceridemia: a contraindication to the use of bile acid binding resins. , 1987, The American journal of medicine.

[7] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[8] J. Stengård,et al. Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.

[9] D. Pryor,et al. Variation in patient utilities for outcomes of the management of chronic stable angina. Implications for clinical practice guidelines. Ischemic Heart Disease Patient Outcomes Research Team. , 1995, JAMA.

[10] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[11] Harold C. Sox,et al. Variation in Patient Utilities for Outcomes of the Management of Chronic Stable Angina: Implications for Clinical Practice Guidelines , 1995 .

[12] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.

[13] J. Danks,et al. Fates worse than death: the role of valued life activities in health-state evaluations. , 1996, Health Psychology.

[14] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[15] N. Stone,et al. Management of lipids in clinical practice , 1997 .

[16] R. Collins,et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[17] A. Gotto,et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[18] T. Wilt,et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[19] N. Wenger,et al. End-of-life decision making , 2000, Journal of General Internal Medicine.

[20] D. Goodenberger. Time for a new paradigm. , 2001, Missouri medicine.

[21] E. Bolson,et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. , 2001, The New England journal of medicine.

[22] M. Ezekowitz,et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. , 2001, JAMA.

[23] J. Mckenney,et al. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[24] S. Yusuf. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[25] Elizabeth H Bradley,et al. Understanding the treatment preferences of seriously ill patients. , 2002, The New England journal of medicine.

[26] S. Grundy,et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. , 2002, Archives of internal medicine.

[27] N. Stone,et al. Goals of statin therapy: three viewpoints. , 2004, Current atherosclerosis reports.

[28] V. Athyros,et al. Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease Prevention , 2002, Current medical research and opinion.

[29] S. Grundy,et al. National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .

[30] Barry R. Davis,et al. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). , 2002, JAMA.

[31] J. Mckenney,et al. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[32] B. Starfield,et al. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. , 2002, Archives of internal medicine.

[33] P. Macfarlane,et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[34] AndrewJ. S. Coats. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[35] P. Serruys,et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[36] H. Origasa,et al. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). , 2003, American heart journal.

[37] M. Pfeffer,et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. , 2004, JAMA.

[38] Neil J Stone,et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[39] R. Collins,et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions , 2004, The Lancet.

[40] S. Grundy,et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[41] D. Hunninghake,et al. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. , 2004, Journal of the American College of Cardiology.

[42] John H Fuller,et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[43] Thomas Weber,et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[44] Irene M Stratton,et al. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. , 2004, Diabetes care.

[45] J. Slattery,et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[46] O. Faergeman,et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.

[47] W. März,et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.

[48] Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[49] R. Collins,et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). , 2005, Diabetes care.

[50] B. Zinman,et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. , 2005, The New England journal of medicine.

[51] A. Laupacis,et al. Preference-Based Antithrombotic Therapy in Atrial Fibrillation: Implications for Clinical Decision Making , 2005, Medical decision making : an international journal of the Society for Medical Decision Making.

[52] Winfried März,et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005 .

[53] Marilyn Rantz,et al. Predicting death in the nursing home: development and validation of the 6-month Minimum Data Set mortality risk index. , 2005, The journals of gerontology. Series A, Biological sciences and medical sciences.

[54] R. Collins,et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[55] J. Hippisley-Cox,et al. Coronary heart disease prevention and age inequalities: the first year of the National Service Framework for CHD. , 2005, The British journal of general practice : the journal of the Royal College of General Practitioners.

[56] P Glasziou,et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[57] A. Hartmann,et al. Long‐term Cardiac Outcomes in Renal Transplant Recipients Receiving Fluvastatin: The ALERT Extension Study , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[58] J. Hsia,et al. Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes , 2006, Diabetes Care.

[59] High-dose Atorvastatin After Stroke or Transient Ischemic Attack , 2006 .

[60] G. Alexander,et al. Reconsidering medication appropriateness for patients late in life. , 2006, Archives of internal medicine.

[61] H. Shimomura,et al. Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. , 2006, The American journal of cardiology.

[62] D. Mikhailidis,et al. Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN) , 2006, Diabetes Care.

[63] M. Hennerici,et al. High-dose atorvastatin after stroke or transient ischemic attack. , 2006, The New England journal of medicine.

[64] E. Braunwald,et al. Coronary heart disease Acute coronary syndromes and diabetes : is intensive lipid lowering beneficial ? Results of the PROVE IT-TIMI 22 trial , 2006 .

[65] Yasuo Ohashi,et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial , 2006, The Lancet.

[66] S. Pocock,et al. Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes , 2006, Diabetes Care.

[67] Jennifer G. Robinson,et al. Is it Time for a Cardiovascular Primary Prevention Trial in the Elderly? , 2007, Stroke.

[68] I. Holme,et al. Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. , 2007, The American journal of cardiology.

[69] C. White,et al. Impact of statin dosing intensity on transaminase and creatine kinase. , 2007, The American journal of medicine.

[70] A. Wierzbicki,et al. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[71] J. Farmer. High-dose atorvastatin after stroke or transient ischemic attack. , 2007, Current atherosclerosis reports.

[72] L. Goldman,et al. Adolescent overweight and future adult coronary heart disease. , 2007, The New England journal of medicine.

[73] D. Herrington,et al. Outcomes of Using High- or Low-Dose Atorvastatin in Patients 65 Years of Age or Older with Stable Coronary Heart Disease , 2007, Annals of Internal Medicine.

[74] H. Bays,et al. Safety considerations with niacin therapy. , 2007, The American journal of cardiology.

[75] W. Howard. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2007 .

[76] S. Bonovas,et al. Use of statins and risk of haematological malignancies: a meta-analysis of six randomized clinical trials and eight observational studies. , 2007, British journal of clinical pharmacology.

[77] Alan G. Ryder,et al. A c c e p t e d M a n u sc r i p t , 2008 .

[78] D. Schwertz,et al. High-Dose Statin Therapy for Secondary Prevention of Stroke: Stroke Prevention by Aggressive Reduction in Cholesterol Levels Study Review , 2008, The Journal of cardiovascular nursing.

[79] Cholesterol Treatment Trialists' Collaborators. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis , 2008, The Lancet.

[80] G. Thompson. Recommendations for the use of LDL apheresis. , 2008, Atherosclerosis.

[81] B. G. Brown,et al. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. , 2008, The American journal of cardiology.

[82] A. LaCroix,et al. Statin use and incident frailty in women aged 65 years or older: prospective findings from the Women's Health Initiative Observational Study. , 2008, The journals of gerontology. Series A, Biological sciences and medical sciences.

[83] L. Tavazzi,et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. , 2008, Lancet.

[84] R Peto,et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. , 2008, Lancet.

[85] P. Libby,et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[86] Gissi-Hf Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[87] D. Capuzzi,et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. , 2008, The American journal of cardiology.

[88] W. Howard. Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes: The Treating to New Targets (TNT) study , 2008 .

[89] Samy I McFarlane,et al. High-dose atorvastatin after stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. , 2008, Journal of the cardiometabolic syndrome.

[90] Edward J. Mills,et al. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. , 2008, Journal of the American College of Cardiology.

[91] 淳一佐々木. Air Force/Texas Coronary Atherosclerosis Prevention Study , 2008 .

[92] J. Kastelein,et al. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. , 2008, Mayo Clinic proceedings.

[93] Y. Ohashi,et al. Usefulness of Pravastatin in Primary Prevention of Cardiovascular Events in Women: Analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA Study) , 2008, Circulation.

[94] J. Kastelein,et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. , 2008, Journal of the American College of Cardiology.

[95] F. Messerli,et al. Impact of systemic hypertension on the cardiovascular benefits of statin therapy--a meta-analysis. , 2008, The American journal of cardiology.

[96] L. Castilla-Guerra,et al. EFFECT OF ATORVASTATIN IN ELDERLY PATIENTS WITH A RECENT STROKE OR TRANSIENT ISCHEMIC ATTACK , 2009, Neurology.

[97] Gert Mayer,et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. , 2009, The New England journal of medicine.

[98] M. Rawlins. De testimonio: on the evidence for decisions about the use of therapeutic interventions , 2008, The Lancet.

[99] J Shepherd,et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials , 2009, BMJ : British Medical Journal.

[100] K. Bainey,et al. Increased burden of coronary artery disease in South-Asians living in North America. Need for an aggressive management algorithm. , 2009, Atherosclerosis.

[101] O. Faergeman,et al. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study). , 2009, The American journal of cardiology.

[102] N. Unwin,et al. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[103] M. Hennerici,et al. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack , 2009, Neurology.

[104] P. Macfarlane,et al. Pravastatin and cognitive function in the elderly. Results of the PROSPER study , 2009, Journal of Neurology.

[105] G. Moneta,et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein , 2009 .

[106] M. Clearfield. Rosuvastatin in older patients with systolic heart failure. , 2009, Current atherosclerosis reports.

[107] S. Daniels,et al. American Heart Association Childhood Obesity Research Summit Report. , 2009, Circulation.

[108] Robert J. Glynn,et al. Rosuvastatin for Primary Prevention in Older Persons With Elevated C-Reactive Protein and Low to Average Low-Density Lipoprotein Cholesterol Levels: Exploratory Analysis of a Randomized Trial , 2010, Annals of Internal Medicine.

[109] Yasuo Ohashi,et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials , 2010, The Lancet.

[110] A. Cass. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. , 2010, American heart journal.

[111] R. Eckel. Approach to the patient who is intolerant of statin therapy. , 2010, The Journal of clinical endocrinology and metabolism.

[112] R. Collins,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[113] L. Cho,et al. Asian Americans and cardiometabolic risk why and how to study them. , 2010, Journal of the American College of Cardiology.

[114] John B Buse,et al. Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.

[115] J Wouter Jukema,et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. , 2010, Archives of internal medicine.

[116] Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. , 2010, American heart journal.

[117] A. Gotto,et al. Relation of different measures of low-density lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapy. , 2010, The American journal of cardiology.

[118] R. Collins,et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. , 2010, Lancet.

[119] W. Lewis,et al. Statins for primary prevention of cardiovascular mortality in women: a systematic review and meta-analysis. , 2010, Preventive cardiology.

[120] R. Collins,et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial , 2010, The Lancet.

[121] S. Studenski,et al. Angiotensin‐Converting Enzyme Inhibitor and Statin Use and Incident Mobility Limitation in Community‐Dwelling Older Adults: The Health, Aging and Body Composition Study , 2011, Journal of the American Geriatrics Society.

[122] Paul Welsh,et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. , 2011, JAMA.

[123] S. Greenfield,et al. Clinical practice guidelines we can trust , 2011 .

[124] M. S. Kirkman,et al. Comment on: American Diabetes Association. Standards of Medical Care in Diabetes—2011. Diabetes Care 2011;34(Suppl. 1):S11–S61 , 2011 .

[125] Guiding the guidelines , 2011, The Lancet.

[126] M. Tinetti,et al. Health outcome prioritization as a tool for decision making among older persons with multiple chronic conditions. , 2011, Archives of internal medicine.

[127] M. Roffi,et al. Current concepts on coronary revascularization in diabetic patients. , 2011, European heart journal.

[128] S. Greenfield,et al. COMMITTEE ON STANDARDS FOR DEVELOPING TRUSTWORTHY CLINICAL PRACTICE GUIDELINES , 2011 .

[129] D. Simons-Morton,et al. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report , 2011, Pediatrics.

[130] M. Tinetti,et al. Effects of benefits and harms on older persons' willingness to take medication for primary cardiovascular prevention. , 2011, Archives of internal medicine.

[131] Harlan M Krumholz,et al. Cardiac care for older adults. Time for a new paradigm. , 2011, Journal of the American College of Cardiology.

[132] Roger B. Davis,et al. External Validation of an Index to Predict Up to 9‐Year Mortality of Community‐Dwelling Adults Aged 65 and Older , 2011, Journal of the American Geriatrics Society.

[133] D. Simons-Morton,et al. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report , 2016, Pediatric Clinical Practice Guidelines & Policies.

[134] F. Veglia,et al. Do statins improve outcomes and delay the progression of non-rheumatic calcific aortic stenosis? , 2011, Heart.

[135] Moshe Levi,et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. , 2011, Circulation.

[136] N. Paynter,et al. Cardiovascular risk prediction in diabetic men and women using hemoglobin A1c vs diabetes as a high-risk equivalent. , 2011, Archives of internal medicine.

[137] William Weintraub,et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. , 2011, The New England journal of medicine.

[138] Dawei Xie,et al. All‐Cause 1‐, 5‐, and 10‐Year Mortality in Elderly People According to Activities of Daily Living Stage , 2012, Journal of the American Geriatrics Society.

[139] R. Brook,et al. Secondary causes of dyslipidemia. , 2012, The American journal of cardiology.

[140] V. Basevi. Standards of Medical Care in Diabetes—2013 , 2012, Diabetes Care.

[141] L. Prosser,et al. Estimated morbidity and mortality in adolescents and young adults diagnosed with Type 2 diabetes mellitus , 2012, Diabetic medicine : a journal of the British Diabetic Association.

[142] P. Libby,et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial , 2012, The Lancet.

[143] M. Barry,et al. Shared decision making--pinnacle of patient-centered care. , 2012, The New England journal of medicine.

[144] A. Yashin,et al. Age Patterns of Incidence of Geriatric Disease in the U.S. Elderly Population: Medicare‐Based Analysis , 2012, Journal of the American Geriatrics Society.

[145] P. Libby,et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial , 2012, The Lancet.

[146] R. Collins,et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. , 2012, Lancet.

[147] R. Collins,et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials , 2012, The Lancet.

[148] F. Sacks,et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. , 2012, The Journal of clinical endocrinology and metabolism.

[149] P. Toth. Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis , 2012 .

[150] M. Drazner,et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[151] M. Lauer,et al. Refocusing the agenda on cardiovascular guidelines: an announcement from the National Heart, Lung, and Blood Institute. , 2013, Circulation.

[152] Jennifer G. Robinson,et al. Heart Association Task Force on Practice Guidelines Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic , 2013 .

[153] R. Varadhan,et al. Support of personalized medicine through risk-stratified treatment recommendations - an environmental scan of clinical practice guidelines , 2013, BMC Medicine.

[154] M. Lauer,et al. Refocusing the agenda on cardiovascular guidelines: an announcement from the National Heart, Lung, and Blood Institute. , 2013, Journal of the American College of Cardiology.

[155] M. Drazner,et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[156] M. Landray,et al. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment , 2013, European heart journal.

[157] M. Jessup,et al. The next steps in developing clinical practice guidelines for prevention. , 2013, Journal of the American College of Cardiology.

[158] Jennifer G. Robinson,et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[159] T. Wadden,et al. Reprint: 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk. , 2014, Journal of the American Pharmacists Association : JAPhA.

[160] Jennifer G. Robinson,et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[161] Janusz Wnek,et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[162] R. Eckel,et al. Reprint: 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk. , 2014, Journal of the American Pharmacists Association : JAPhA.

[163] Diane Lacaille,et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk , 2014 .